Colchicine, Osteoarthritis Progression, and Knee and Hip Replacements
Among 5,522 patients with chronic coronary artery disease in the LoDoCo2 (Low-Dose Colchicine 2) trial, colchicine 0.5 mg daily was associated with a 31% lower incidence
Among 5,522 patients with chronic coronary artery disease in the LoDoCo2 (Low-Dose Colchicine 2) trial, colchicine 0.5 mg daily was associated with a 31% lower incidence
Radiographic, dermatological, and oral manifestations of medication-related osteonecrosis of the jaw are illustrated in an Images in Clinical Medicine feature: “Medication-related osteonecrosis of the jaw
In a phase 2a trial, the humanized IgG1 monoclonal antibody peresolimab demonstrated potential efficacy in 98 adults with rheumatoid arthritis. This agent stimulates the endogenous
In the ASPirin in Reducing Events in the Elderly (ASPREE) trial, older adults with gout taking allopurinol had a reduced risk of persistent physical disability,
For the decade after a 2010 hike in the price of colchicine, patients with gout turned to allopurinol and oral corticosteroids and more frequently visited
Adults with osteoporosis had a lower incidence of type 2 diabetes when treated with denosumab compared with oral bisphosphonates, a population-based study shows. “This study
Withdrawal of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) may be possible in some patients with rheumatoid arthritis (RA), according to the authors of a research
Conflicting data on the effectiveness of the oral Janus kinase 1 and 2 inhibitor baricitinib in patients with systemic lupus erythematosus (SLE) come from a
“As we increase our understanding of the immunologic continuum from a healthy immune system to preclinical rheumatoid arthritis to early and chronic disease, new opportunities
In a pair of phase 3 trials, bimekizumab — a monoclonal immunoglobulin G1 antibody that inhibits interleukin (IL)-17A and -17F — was superior to active